Stock SPRO SPERO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Spero Therapeutics, Inc.

Equities

SPRO

US84833T1034

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-04-26 EDT 		5-day change 1st Jan Change
1.46 USD +2.10% Intraday chart for Spero Therapeutics, Inc. +4.29% -0.68%
03-13 Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
03-13 Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update
AQ
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024
AQ
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections
AQ
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference
AQ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Spero Therapeutics Provides Corporate Update and 2024 Outlook
AQ
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections
AQ
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update
AQ
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
AQ
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
BU
Spero Therapeutics to Present at Upcoming November Investor Conferences
AQ
Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer
AQ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Purcell & Lefkowitz LLP Is Investigating Spero Therapeutics, Inc. (NASDAQ: SPRO) for Potential Breaches of Fiduciary Duty By Its Board of Directors
PR
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Spero Therapeutics to Present at Cantor’s Global Healthcare 2023 Investor Conference
AQ
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
AQ
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update
AQ
Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SPRO Stock
  4. News Spero Therapeutics, Inc.
  5. Press Releases